This guidance document describes Health Canada’s expectations for distributing information
about a prescription drug product using an electronic platform linked to that product’s label.
This document should be read in conjunction with the accompanying notice and the relevant sections of other applicable guidance documents.
22 1.2 Scope and application
The scope of this document is currently limited to prescription drugs for human use. The use of electronic labelling for the purpose of a clinical trial is not within the scope of this document.
This document applies to product-specific electronic platforms, containing drug and other
information, that are linked to prescription drug labels.
In this context, an electronic platform refers to any type of electronic technology used to
distribute information. Websites are a common example of an electronic platform…